BioRegnum: The miracle drug story that just won’t die
Bioregnum
The view from Endpoints
Eight years ago resveratrol was the miracle drug of the hour. Linked to preclinical evidence that it could expand the life spans of mice, GlaxoSmithKline paid a whopping $720 million in cold, hard cash to get its hands on Sirtris, the biotech startup that promised to deliver an anti-aging miracle by turning an ingredient in red wine into a medical reality.
Queue the jokes about drinking more red wine for better health. This is the stuff headlines are made of, and I was happy to participate.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.